NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis $11.25 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.10 -0.15 (-1.29%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kura Oncology Stock (NASDAQ:KURA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kura Oncology alerts:Sign Up Key Stats Today's Range$11.01▼$11.5250-Day Range$7.73▼$11.2552-Week Range$5.45▼$12.49Volume2.49 million shsAverage Volume1.66 million shsMarket Capitalization$998.66 millionP/E RatioN/ADividend YieldN/APrice Target$26.38Consensus RatingModerate Buy Company Overview Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies. The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers. In addition to tipifarnib, Kura Oncology is developing a pipeline of targeted agents, including selective inhibitors of FGFRs, WEE1, and other kinases implicated in oncogenic signaling. Several of these programs are in early-stage clinical trials, and preclinical efforts aim to expand into combination strategies and additional genetic subsets of cancer. Since its founding in 2011, Kura has built a multidisciplinary team of scientists and clinicians to drive its translational research efforts. Under the leadership of Chief Executive Officer Troy Wilson, the company has established strategic partnerships and secured funding to support its clinical development milestones. Kura’s board and management team bring extensive experience in oncology drug development, regulatory affairs, and commercialization, positioning the company to advance its novel therapies through late-stage trials. Kura Oncology primarily operates in the United States, collaborating with leading cancer centers and research institutions to conduct and monitor its clinical studies. The company’s strategic focus on genetically defined patient populations aligns with broader trends toward precision oncology, aiming to deliver therapies that improve outcomes for patients with specific tumor profiles. Looking ahead, Kura plans to continue advancing its pipeline and exploring potential collaborations to broaden the reach of its targeted cancer treatments.AI Generated. May Contain Errors. Read More Kura Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreKURA MarketRank™: Kura Oncology scored higher than 48% of companies evaluated by MarketBeat, and ranked 536th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKura Oncology has a consensus price target of $26.38, representing about 134.4% upside from its current price of $11.25.Amount of Analyst CoverageKura Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kura Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($3.23) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 9.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kura Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.81% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 11.73, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently increased by 2.82%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.01 News SentimentKura Oncology has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 6 articles on an average week.Search Interest21 people have searched for KURA on MarketBeat in the last 30 days. This is an increase of 320% compared to the previous 30 days.MarketBeat Follows1 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Kura Oncology is held by insiders.Percentage Held by InstitutionsKura Oncology has minimal institutional ownership at this time.Read more about Kura Oncology's insider trading history. Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KURA Stock News HeadlinesBank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)May 23 at 8:34 AM | theglobeandmail.comKura Oncology to Present at TD Cowen 7th Annual Oncology Innovation SummitMay 19, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Kura Oncology (KURA) Receives a Buy from LifeSci CapitalMay 17, 2026 | theglobeandmail.comSome Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) EstimatesMay 17, 2026 | finance.yahoo.comEarnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their ForecastsMay 15, 2026 | finance.yahoo.comKura targets 2028 first top line KOMET-017 Phase III results as KOMZIFTI posts $5.8M in first full launch quarterMay 14, 2026 | seekingalpha.comKura Oncology (KURA) Receives a Buy from BarclaysMay 14, 2026 | theglobeandmail.comSee More Headlines KURA Stock Analysis - Frequently Asked Questions How have KURA shares performed this year? Kura Oncology's stock was trading at $10.39 at the beginning of the year. Since then, KURA shares have increased by 8.3% and is now trading at $11.25. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.05. The business earned $18.27 million during the quarter, compared to analysts' expectations of $25.97 million. Kura Oncology had a negative trailing twelve-month return on equity of 141.95% and a negative net margin of 411.19%. Read the conference call transcript. When did Kura Oncology's stock split? Kura Oncology shares reverse split before market open on Friday, October 18th 2024.The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kura Oncology IPO? Kura Oncology (KURA) raised $90 million in an IPO on Thursday, November 5th 2015. The company issued 14,279,820 shares at a price of $6.32 per share. Who are Kura Oncology's major shareholders? Top institutional investors of Kura Oncology include Renaissance Technologies LLC (1.78%), Dimensional Fund Advisors LP (1.61%), Bank of America Corp DE (1.39%) and Pale Fire Capital SE (0.97%). Insiders that own company stock include Mollie Leoni, Troy Edward Wilson, Teresa Brophy Bair, Brian T Powl, Kathleen Ford, Thomas James Doyle, Thomas Malley and Francis Burrows. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Company Calendar Last Earnings5/12/2026Today5/25/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/26/2026Study update6/03/2026Status update6/12/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, KURA's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KURA CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees130Year Founded2007Price Target and Rating Average Price Target for Kura Oncology$26.38 High Price Target$40.00 Low Price Target$15.00 Potential Upside/Downside+134.4%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$278.67 million Net Margins-411.19% Pretax Margin-411.08% Return on Equity-141.95% Return on Assets-43.28% Debt Debt-to-Equity Ratio0.09 Current Ratio6.15 Quick Ratio6.14 Sales & Book Value Annual Sales$67.48 million Price / Sales14.80 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book9.22Miscellaneous Outstanding Shares88,770,000Free Float82,027,000Market Cap$998.66 million OptionableOptionable Beta0.32 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:KURA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
